e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

153.44 -0.81 (-0.53%)

Official Closing Price Updated: 7:00 PM EDT, Mar 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

55 56 Next >

3 Unstoppable Stocks to Buy and Hold for Decades ↗

October 17, 2023

These stocks can be pillars for your long-term portfolio, and investing in all three offers excellent diversification.

Via The Motley Fool

Why Top 1% Biotech MoonLake Just Surged Within Striking Distance Of A Breakout ↗

October 16, 2023

MoonLake says it's skin-disease treatment showed improved promise in a 24-week testing update.

Via Investor's Business Daily

Weight Loss Drugs Market Size, Share, Growth, Trends, Analysis 2028

October 13, 2023

Get an extensive Weight Loss Drugs Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry.

Via SBWire

Antiparasitic Drugs Market to See Major Growth by 2023-2030 : Arbor Pharmaceuticals, GlaxoSmithKline, Cipla

October 11, 2023

Get an extensive Antiparasitic Drugs Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry.

Via SBWire

RayzeBio Is A New Contender in Radiopharmaceutical Arena, Will Attract Prominent Entities: JP Morgan ↗

October 10, 2023

JP Morgan has initiated coverage on RayzeBio Inc (NASDAQ: RYZB), representing a pure-play opportunity in the radiopharmaceutical space.

Via Benzinga

Cancer Immunotherapies Market Set for More Growth : American Cancer Society, WebMD, Eli Lily and Company

October 10, 2023

Get an extensive Cancer Immunotherapies Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry.

Via SBWire

AbbVie Stock Moves Higher With Rising Relative Strength ↗

October 10, 2023

A Relative Strength Rating upgrade for AbbVie shows improving technical performance. Will it continue?

Via Investor's Business Daily

Elsevier Launches New Pharmapendium, Empowering Pharma Companies to Bring Novel Drugs to Market Faster and Increase Success of Regulatory Submissions

October 10, 2023

London, United Kingdom--(Newsfile Corp. - October 10, 2023) - Elsevier, a global leader in information and data analytics, has launched...

Via Newsfile

Topics Animal Testing

3 Artificial Intelligence Stocks That Could Outperform the ‘Godfather of AI’ ↗

October 09, 2023

These are the AI stocks to buy and hold for multibagger returns in the next 24 months, as they represent quality growth companies.

Via InvestorPlace

Topics Artificial Intelligence

Eli Lilly, McKesson, Novartis Flash Promising Chart Action

October 09, 2023

Eli Lilly, McKesson, and Novartis are catching investors' attention with promising chart patterns and revenue growth, signaling potential buying opportunities.

Via MarketBeat

Protecting Cannabis Products & More: New Sustainable Child-Resistant Packaging By Dymapak ↗

October 05, 2023

Dymapak, a global manufacturer specializing in innovative child-resistant packaging solutions for various industries, has introduced a child-resistant Consumer Packaged Goods (CPG) packaging...

Via Benzinga

Topics Cannabis

Novartis Shares Decline As Spin Off Sandoz's Market Debut Falls Short of Expected Valuation ↗

October 04, 2023

Sandoz Group AG (OTC: SDZNY) (OTC: SDZXF) enters a new era as a standalone player in generic and biosimilar medicines.

Via Benzinga

SDZNY Stock: 7 Things to Know as Novartis Spinoff Sandoz Starts Trading Today ↗

October 04, 2023

Sandoz (SDZNY) stock is a hot topic among traders on Wednesday as the company starts trading after a spinoff from Novartis.

Via InvestorPlace

Why Cal-Maine Foods Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

October 04, 2023

Gainers Gaucho Group Holdings, Inc. (NASDAQ: VINO) jumped 95.2% to $3.7280. Gaucho Group is planning to list two of its retail properties in Argentina, in San Rafael and Cordoba, for sale, priced at $2...

Via Benzinga

Cancer Drug Maker 3D Medicines Inc. Trading Higher After Company Announces It Will Repurchase Up To 10% Of Outstanding Shares ↗

October 04, 2023

3D Medicines Inc. was trading 7.2% higher in the Hong Kong Wednesday morning session at HK$5.53 after the company announced that it is buying back up to 10% of its own stock.

Via Benzinga

Cal-Maine Foods, A10 Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

October 04, 2023

U.S. stock futures traded mixed this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Novartis Mulls Divesting Some Assets Of Radiopharma Unit In Strategic Shift ↗

October 03, 2023

Swiss pharmaceutical giant Novartis AG (NYSE: NVS) is reportedly contemplating selling sections of radiopharmaceuticals company Advanced Accelerator Applications to align with the company's strategy...

Via Benzinga

Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration ↗

October 03, 2023

All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of them are suing the administration

Via Benzinga

Novartis' Investigational Therapy Shows Promising Action In Rare Kidney Disease ↗

October 02, 2023

Novartis AG (NYSE: NVS) announced topline results from the pre-specified interim analysis of the Phase 3 APPLAUSE-IgAN study at nine months of iptacopan, an investigational factor B inhibitor targeting...

Via Benzinga

Cardiol Therapeutics 76% YTD Gain Is A Bullish Signal Ahead Of Expected Phase III Trial Announcements ($CRDL)

October 02, 2023

Via AB Newswire

Topics Death

Fusion Pharmaceuticals Poised For Leadership In Targeted Cancer Therapies: Oppenheimer ↗

September 29, 2023

Oppenheimer initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), citing the company's pipeline as among the best in the space with alpha-emitter-based targeted radionuclide therapies...

Via Benzinga

Allakos' Antibodies For Chronic Skin Conditions, Analyst Sees Over 400% Stock Upside ↗

September 27, 2023

JMP Securities initiated coverage on Allakos Inc (NASDAQ: ALLK), noting novel monoclonal antibodies targeting Siglec (sialic acid immunoglobulin-like lectin) receptors on immune cells that are drivers...

Via Benzinga

Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges ↗

September 27, 2023

Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY

Via Benzinga

Health Insurer Centene Streamlines - Plans Massive Layoffs To Cut Costs: Report ↗

September 27, 2023

Centene Corporation (NYSE: CNC) is reportedly laying off about 3% of its workforce as the health insurer plans to cut expenditures and accelerate profits over the years.

Via Benzinga

Topics Workforce

Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023 ↗

September 25, 2023

Via Benzinga

Amazon Invests $4B In ChatGPT Competitor, Hollywood Writers Accept Tentative Deal, ChatGPT Challenges Siri And Alexa With Introduction Of Verbal Responses: Today's Top Stories ↗

September 25, 2023

Benzinga

Via Benzinga

Novartis Sandoz Prepares For Public Debut With Strong Sales Record And Plans for New Biologic Drugs ↗

September 25, 2023

Novartis AG (NYSE: NVS) confirmed its plans for a 100% spin-off of the Sandoz business on October 4 after shareholders approved it

Via Benzinga

Are Gene Therapy Stocks The Market's Next Big Winners?

September 25, 2023

Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.

Via MarketBeat

Topics Artificial Intelligence

Novartis Precision Cancer Therapy Hits Primary Goal In Rare Type Of Pancreatic Cancer ↗

September 25, 2023

Novartis AG (NYSE: NVS) released topline data from the Phase 3 NETTER-2 trial with Lutathera, a radioligand therapy (RLT) for advanced gastroenteropancreatic

Via Benzinga

Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement ↗

September 23, 2023

Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. The company will make...

Via Talk Markets

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

55 56 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy